Introduction
Ischemic stroke is a major cause of death and disability. Alteplase, a recombinant tissue plasminogen activator(rtPA) , is still the only approved medication for administration within 3 to 4.5 hours for patients undergoing an acute ischemic stroke (AIS).
1 However, reperfusion injury, including hemorrhagic transformation or massive edema can accompany alteplase administration; 2,3 therefore, the use of this thrombolytic therapy can become a dilemma, particularly for patients with large infarct.
The high incidence of spontaneous hemorrhagic transformation in AIS patients has been documented, ranging from 38% to 71% in autopsy studies and from 13% to 43% in clinical trials. 4, 5 Notably, alteplase-treated stroke patients have a 10-fold higher risk of suffering an intracranial hemorrhage than untreated patients. 3 Hemorrhagic transformation after thrombolysis is generally an early event (<24 hours), as documented in the NINDS rtPA trial, in which all fatal parenchymal hemorrhages occurred in this time period, with 80% occurring within 12 hours of treatment delivery. 3 In addition, the patients' brain water content also rises due to vasogenic edema that occurs within 1 to 4 hours of stroke onset, peaks between day 3 to 8 and vanishes at day 30. [6] [7] [8] [9] Such edema enlarges lesion volume in 10% of ischemic strokes, evoking the malignant middle cerebral artery occlusion syndrome. Severe edema and mass effect are associated with an up to an 80% mortality rate in malignant middle cerebral artery occlusion. 10 Brain ischemia and reperfusion activate the immune system. This abrupt and massive influx of lymphocytes from the periphery into the ischemic region orchestrates a focal inflammatory response, further disrupts the blood-brain barrier (BBB) and worsens the clinical outcomes of these patients. Early BBB disruption and pronounced inflammatory response elicited by ischemia and cell death play a critical role in lesion enlargement, hemorrhagic rials. 4, 5 Notably, alteplase-treated stroke patients have a 10-fold higher risk of su uff ff ffer er erin in ing g g an an an ntracranial hemorrhage than untreated patients. 3 Hemorrhagic transformation after thrombolysis s g gen en ener er eral al ally ly ly a a an ea a arl rl rly event (<24 hours), as docume me ment n n ed in the NINDS r rtP tP tPA A A trial, in which all fatal p p pare e enchymal he e emo mo m rr r rh ha hage ge ges s s oc oc occu cu curr r red ed ed i i in n n th his t t tim m ime per r riod, d, d, w w wit it ith h h 80 80 0% % % oc oc occu cu curr r r i ing wi wi with th thin in in 1 1 12 2 h h hour ur urs s s of of of re ea eatm tm tment de e eli li livery ry ry. . . 3 In n n a a additio io ion, n, n, the e e p p pat t tie e ents' s' ' b b brain n w w wat t ter r r co o ont nt nten en nt t al l lso o o ris se es d d due ue ue to va va vas s soge en n nic ed ed edem em ema a a th th that at at o o occ cc ccur r urs s s wi i with th thin in in 1 1 1 t t to o o 4 4 4 ho ho hour r urs s s of of of s s str tr trok ok oke e e on on onse se set t t, p p pea ea eaks ks ks b b bet et etwe e ween en en d d day a ay 3 3 3 t t to o o 8 8 8 an an and d d va a vani ni nish sh shes es es a a at t t transformation and vasogenic edema. 7, 11 In addition, inflammation promotes hemorrhagic transformation and vasogenic edema as well as worsening reperfusion injury associated with the use of alteplase within 4.5 hours after ischemic stroke begins. [12] [13] [14] Therefore, we hypothesize that suppression of inflammation might not only attenuate immune-mediated brain damage as a monotherapy, but also would be a fitting complement to reperfusion thrombolytic therapy.
Fingolimod is a sphingosine analog that acts on sphingosine-1-phosphate receptors. It was approved by the FDA in 2010 as the first oral disease-modifying therapy for the relapsingremitting form of multiple sclerosis. 15 Fingolimod inhibits the egress of lymphocytes from lymph nodes and limits their recirculation. 16 Additional effects on the integrity of BBB and direct action on neurons and glia that bear S1PR may also contribute to its beneficial attributes in multiple sclerosis. [17] [18] [19] Recently, the safety and efficacy of fingolimod in both intracerebral hemorrhage (ICH) and AIS patients have been investigated in proof-of-concept trials. 20, 21 In ICH, fingolimod treatment for 72 hours produced short term and long term clinical benefits as well as limiting the expansion of perihematomal edema. 20 In patients with acute anterior circulation occlusion, who are later than 4.5 hours after disease onset and otherwise ineligible for alteplase, fingolimod significantly improved the clinical outcome, reduced secondary lesion growth and decreased microvascular permeability. 21 However, the safety and efficacy of early treatment with fingolimod in AIS patients eligible for alteplase (<4.5 hours after initial onset) are not known.
The aim of this study was to investigate the safety and preliminary impact of co-administration of fingolimod with alteplase on clinical outcomes, hemorrhagic transformation and magnitude of edema in AIS patients.
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Methods

Study design and patients
This randomized, open-label, evaluator-blind, multicenter pilot trial was performed between 2013 and 2015 at three stroke centers in Tianjin, China. Enrollment included 47 patients with first-ever hemispheric ischemic stroke, ages 18-80 and > 5 on NIHSS score. Exclusion criteria were patients with (1) standard contraindications to alteplase; (2) evidence of other diseases of the CNS; (3) pre-existing neurologic disability (a score greater than 2 on the modified Rankin Scale -mRS); (4) swallowing difficulties (defined by bedside dysphagia evaluation); (5) patients with any history of bradyarrhythmia or atrioventricular blocks; (6) concomitant use of antineoplastic, immunosuppressive or immune-modulating therapies; (7) macular edema. In addition, we used specific selection criteria for this trial that were based on the results of MRI imaging. The MRA inclusion criterion was the presence of intracranial occlusion in the anterior cerebral or middle cerebral artery. Patients with internal-carotid-artery and vertebrobasilar artery occlusions were excluded due to safety and variability concern.
Patients were randomly assigned in a 1:1 ratio to receive either the standard dose of alteplase (0.9 mg per kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg) or the standard dose of alteplase plus fingolimod (Gilenya, Novartis). Each patient in the fingolimod plus alteplase group was given 0.5 mg of fingolimod orally once daily, for three consecutive days, with the first dose being given before alteplase administration (Figure 1) . Randomization was performed by means of a coin toss by Pa Pa Pati ti tien en ents ts ts wer er ere e e ra ra rand nd ndom om omly l ly a a ass ss ssig ig igne ne ned d d in in in a a a 1 1 1:1 :1 :1 r r rat at atio io io t t to o o re re rece ce ceiv i ive e e ei ei eith th ther er er th th the e e st st stan an anda da dard rd rd d d dos os ose e e of of of procedures were approved by the institutional review board at each participating center. This study is registered with ClinicalTrials.gov, number: NCT02002390.
Procedures
FACS assessments
The kinetics of lymphocyte subset alteration were monitored in whole-blood samples from all fingolimod-treated patients at the baseline, which preceded the first dose, and at day 1, day 7
and day 90 after the first dose for comparison with untreated patients at the same time points.
Mononuclear cells were isolated from the whole-blood specimens and stained with antibodies to 
Clinical assessments
Patients' demographics and risk-factor characteristics were recorded. Hypertension was defined as systolic blood pressure greater than 140 mm Hg and/or diastolic blood pressure greater than 90 mm Hg; diabetes was defined as a fasting plasma glucose greater than or equal to 7.0 mmol/L and/or plasma glucose two hours after a meal greater than or equal to 11.1 mmol/L. Hyperlipidemia was defined as a serum total cholesterol levels greater than 5.72 mmol/L and/or triglycerides more than 1.7 mmol/L. Clinical assessments were performed by neurologists (X. X., Y. F. and N. S.) upon patients' enrollment, at the time points when alteplase was given and on days 1, 7, 14 and 90 afterward in an evaluator-blinded fashion (Figure 1) . The extent of neurologic deficit was evaluated by NIHSS. Recovery outcomes at 90 days were assessed with mRS.
Imaging protocol
Noncontrast CT imaging was performed to exclude cerebral hemorrhage in patients prior were acquired using a FACSCalibur (Becton Dickinson Immunocytometry System em ms, s, s, S S San an an J J Jos os ose e, e CA, USA) and analyzed with Flow Jo software (Tree Star, Ashland, OR, USA).
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P P Pati i ients' demogr gr grap phi hi ic c cs a a and nd nd ris is isk-k-k-f f fac ac acto to t r r ch harac ac acte e erist tic c cs we we wer re re r r rec ec ecor rd With regard to the type of hemorrhage, such transformation can be divided into hemorrhagic infarction and parenchymal hematoma defined as signal loss on GRE imaging.
Petechial hemorrhagic transformation was defined as punctate areas of signal loss within the stroke bed on GRE imaging without any significant mass effect or intraventricular extension.
Parenchymal hematoma was defined as a homogeneous, confluent area of signal loss with mass effect and/or intraventricular extension. 23 Symptomatic intracranial hemorrhage was defined as a large parenchymal hematoma combined with a significant clinical deterioration of 4 points on the NIHSS.
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Wi Wi With th th r r reg eg egar ar ard d d to to to t t the he he t t typ p ype e e of of of h h hem em emor or orrh rh rhag ag age e e, su s such ch ch t t tra ra rans ns nsfo fo form rm rmat at atio io ion n n ca ca can n n be be be d d div i ivid id ided ed ed i i int nt nto o o hemorrhage volume was measured on GRE (day 1). Measurements were performed independently by two blinded neuroradiologists (W.H. and Y.F.) using MIPAV software. Lesion volume and hemorrhage volume were manually outlined on the DWI, Flair and GRE slices and then automatically calculated for each slice from the measured area and corresponding slice thickness.
Outcomes
The primary outcomes were changes in lesion volume from baseline (DWI) to day 1 (Flair), the hemorrhage volume (GRE) at day 1 and extent of clinical improvement at day 1, as measured by the changes on the NIHSS score from baseline to day 1. Secondary outcomes were the extent of lesion volume growth from day 1 to day 7, extent of clinical improvement from day 1 to day 7 and the probability of excellent recovery at day 90 (defined as a score of 0 or 1 on the mRS).
Statistical analysis
Before the completion of the study, a biostatistician developed the statistical analysis plan to test the prespecified trial hypotheses defined in the protocol. The primary hypothesis was that a comparison between the alteplase group and the fingolimod plus alteplase group would show the superiority of fingolimod plus alteplase with respect to one or more primary outcomes (change in lesion volume at day 1, hemorrhage volume at day 1 or NIHSS change at day 1). An alpha level of 0.05 was prespecified for each of the three primary end points. We calculated the sample size for the current study on the basis of our pilot study, 21 with the power set at 80% and an assumption of superiority with respect to one of the three primary outcomes, at an alpha level of 0.05. and the probability of excellent recovery at day 90 (defined as a score of 0 or 1 on the mRS).
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Results
Baseline characteristics of patients Figure 1 shows the screening profile of the trial. Between 2013 and 2015, a total of 620 patients potentially eligible for intravenous thrombolysis underwent screening within 4.5 hours after symptom onset. Of these patients, 47 (8%) were enrolled in the study. Patients with internalcarotid-artery occlusion, basilar-artery occlusion, an absence of intracranial vessel occlusion or dysphagia were excluded from the study. The median (range) NIHSS score at baseline for all enrolled patients was 12 (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Of the 47 enrolled patients, 25 were randomly assigned to the alteplase group (treated with alteplase only) and 22 were assigned to the fingolimod plus alteplase group (treated with alteplase plus fingolimod). Most baseline clinical characteristics were well matched among the two groups, except the fingolimod plus alteplase group included more persons who had atrial fibrillation (P = 0.030; Table 1 ). Patients in the control group received treatment at a mean of 3.0 hours, as compared with 3.1 hours for those in the fingolimod-treated groups (P = 0.73). There were no significant differences in the sites of occlusion at baseline (P = 0.29) or infarct volumes (P = 0.90) at baseline among the groups.
Alteration of lymphocytes after oral fingolimod
We used circulating lymphocyte counts to confirm the biological activity of fingolimod at a dosage of 0.5mg. At baseline, the numbers of CD4 + T, CD8 + T, CD19 + B and CD56 + natural ymptom onset. Of these patients, 47 (8%) were enrolled in the study. Patients wi i ith th th i i int nt nter er erna na nal-l-lcarotid-artery occlusion, basilar-artery occlusion, an absence of intracranial vessel occlusion or f dysp p pha ha hagi gi gia a a we we were e e ex xc xcluded from the study. The me me medi di dia an a (range) NIHSS s sco co core at baseline for all en en enro o olled patient t ts s s w wa as s s 12 12 12 ( ( (6-6-6-22 22 22). ). ). O O Of f f th th the e e 4 47 e en n nro ol o led d p p pat tie ie ient nt nts, s, s, 2 2 25 we we were re re r r ran an and doml ml mly y y as as ssi si sign gn gned ed ed to o o th th the e e d al l lte te tepl pl plase grou ou oup ( (t ( re e eate e ed with h h al al alte t t pl pl plas as ase on n nly y y) ) ) an n nd 2 22 we e ere e e as s ssig ig gne ne ned to to o th he fin ngo go goli l l steady reductions of these cell counts were recorded on day 1 after fingolimod administration, these were 54% (P < 0.01), 61% (P < 0.01), 59% (P < 0.01) and 58% (P < 0.01) decreases from baseline in CD4 + T cells, CD8 + T cells, CD19 + B cells and NK cells, respectively (Figure 2) .
The swift action of fingolimod on blood lymphocytes makes it potentially feasible to combine fingolimod (0.5mg) with alteplase treatment in acute ischemia. On the subsequent day 7
analyses, lymphopenia was consistently seen in fingolimod-treated patients. On the day 90 follow up, the total lymphocyte counts returned to baseline levels.
Clinical and MRI outcomes in patients receiving alteplase alone or combined with fingolimod
For all 47 patients, baseline and follow-up DWI, FLAIR, GRE and MRA images were available for analysis. There was no difference in the recanalization rates between groups on day 1 (P =0.77); 14 (64%) patients in the fingolimod plus alteplase group and 17(68%) patients in alteplase group experienced recanalization.
Compared to patients who received alteplase only, the addition of fingolimod appeared to be associated with better outcomes on all three primary end points adopted by the study ( for an an anal al alys ys ysis is is. . . Th T T e er ere e e was no difference in the recan an anal al aliz i i ation rates betwee e en n n gr g g oups on day 1 (P = = =0.7 7 77); 14 (64%) %) %) p pat at tie ie ient nt nts s s in in in t t th h he e e fi fi fing ng ngol ol olim mod od d pl lu l s a alt t tepl l las as ase e gr gr grou ou oup p an n nd d d 17 17 17(6 68% % %) ) ) pa pa pati ti tien en ents s s i i in al l lte te tepl pl plase gr rou ou oup ex ex exp pe p ri i ien n nced d re re r ca c c na a ali li liza a atio on o .
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Fingolimod was also beneficial with respect to secondary outcomes (Figure 4) . In comparison with patients who received alteplase only, patients who received the combination of fingolimod and alteplase exhibited a significant reduction of lesion volume growth (-2.3 ± 2.7 vs 12.1 ± 3.7 ml, P < 0.01), and decreased NIHSS scores (2.5 (0-7) vs 1 (-4-5), P < 0.01) from day 1 to day 7; a higher proportion of these patients experienced good recovery (mRS 0-1) by day 90 (73% vs 32%, P = 0.01).
These results indicate that the addition of fingolimod was probably responsible for inhibiting hemorrhagic transformation and edema at early time points (less than 24 hours) and restrained the extension of lesion volume at later time points (from day 1 to day 7) as representative MRIs showed in Figure 5 .
Safety
Suspected lung infection and urinary tract infection occurred in 14% and 9% of the fingolimod plus alteplase-treated patients and in 12% and 8% of alteplase-only patients, respectively ( Table   2 ). Infection signs in fingolimod plus alteplase-treated patients were relatively mild and resolved after a brief course of antibiotics. No recipient of fingolimod complained of chest discomfort.
ECG monitoring found no cardiac arrhythmia or atrioventricular blocks. In addition, blood pressure, heart rate and routine laboratory investigations before and after the treatment showed no obvious fluctuations (Table s- 
Discussion
In this study, we found that fingolimod plus alteplase was superior to alteplase alone with respect to lesion volume enlargement, hemorrhage volume and clinical improvement at 24 hours after estrained the extension of lesion volume at later time points (from day 1 to day 7) 7) 7) a a as s s epresentative MRIs showed in Figure 5 .
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Clinical factors such as a high initial NIHSS, delayed treatment time, high blood pressure, atrial fibrillation, cerebral embolism, hyperglycemia and recanalization status are well known to increase the incidence of hemorrhagic transformation. 11 In this trial, there was no difference between the two groups of patients in terms of these predictors except that more patients had atrial fibrillation in the fingolimod plus alteplase group (8 / 22 vs 2 / 25). At the baseline, patients enrolled in the fingolimod plus alteplase group were expected to be more prone to bleeding compared with the patients in the alteplase group on the basis of the former's higher rate of atrial fibrillation. To the contrary, however, no increase in the probability of bleeding or severity of hemorrhagic transformation was identified in this group of patients who received the combination therapy of fingolimod and alteplase. Thus, our findings suggest that fingolimod was effective in preventing hemorrhagic transformation associated with alteplase administration.
Abnormal permeability of the BBB resulting from ischemic endothelial dysfunction of capillaries and strong inflammatory reaction underlies both brain edema and hemorrhagic transformation of ischemic brain tissue at the earlier time after alteplase treatment. 7, 11 In addition, alteplase may degrade the integrity of the extracellular matrix and increase the risk of pressure, atrial fibrillation, cerebral embolism, hyperglycemia and recanalization s s sta ta tatu tu tus s s ar ar are e e we we well known to increase the incidence of hemorrhagic transformation. 11 In this trial, there was no diff fer er eren en ence ce ce b b bet et e we e een en n the two groups of patients in n n te te ter rm rms of these predicto o ors s s except that more p p pati i ients had atr r ria ia ial fibr br bril illa la lati ti tion on on i i in n n t t the he he f f fin in ingo oli i imo mo mod d pl lus s s alt t tep ep epla la lase se se g grou ou oup p p (8 (8 (8 / / / 2 22 vs vs vs 2 2 2 / / / 2 2 25) 5) 5). A A At t t the he he ba a ase se seli li l ne, pa ati ti tie e ents s s e e enro o olled in n n the he he fin n ng go gol l lim mo m d d d pl pl plus a a alt t tepl pl pla as ase g gr grou ou oup p p w we were r r e e ex xpec c cte e ed to b b be e e m mor r re pro r ron ne o o o b b ble le leed ed edin in ing g g co co comp mp mpar ar ared ed ed wit it ith h h th th the e e pa pa pati ti tien en ents ts ts i i in n n th th the e e a a alt lt ltep ep epla la lase se se g g gro ro roup p up o o on n n th th the e e ba ba basi si sis s s of of of t t the he he f f for or orme me mer' r' r's s s hi hi high gh gher er er hemorrhagic transformation. 24 We showed that fingolimod combined with alteplase reduced lesion volume expansion, mainly derived from vasogenic edema, 8 BBB B B in in inju ju jury ry ry a a and r r red ed educed risk of brain hemorrhag g ge e e ha h h ve been reported i in n n a a a mouse model of h h hro o omboembolic ic ic st trok ok oke af af afte te ter tr tr tre ea eatm tm tme e ent nt nt w wit th h h al l ltepl las s se pl pl plu us us f f fin in ingo goli li l mo mo mod d d. 25 25 25 Betw w we ee e n th h he ac c cu ut u e an n nd s su s ba a acu c c te te e s s stag g ge i in st tro o oke e e, v v vaso so oge ge geni ni ic ed ed dem em ma a in nc c cre e eases s s th th the l les s sion vo o volu l lume me me vis is isib ib ible le le o o on n n MR MR MRI I I, p p pea ea eaki ki king ng ng b b bet et etwe e ween en en 3 3 3 t t to o o 8 8 8 da da days s ys a a aft ft fter er er i i ict ct ctus s us, af af afte te ter r r wh h whic ic ich h h th th that at at vol ol olum m ume e e be be begi gi gins ns ns inflammation injury is the main target of fingolimod. For that reason, we quantified the changes of lesion size from day 1 to day 7, which we deem to be a secondary outcome. A remarkable restriction in lesion growth between day 1 and day 7 was observed in patients who received the combination of fingolimod and alteplase, as compared to that in patients who received alteplase only (-2.3 vs 12.1ml). These findings confirmed the previous results that fingolimod limits the extent of lesion enlargement when fingolimod was administrated at a later time point, a mean of 20 hours after onset 21 . Further, it is important to note that the limitation of lesion expansion was more pronounced in the current study when fingolimod was administered at a mean time of 3.1 hours after disease onset. Thus, the current results imply that early immune modulation using fingolimod, with or without i.v. thrombolysis, appears to provide a beneficial impact on clinical and radiographic outcome in these patients, and an added-on effect in patients receiving thrombolytic therapy plus fingolimod.
Limitations of this study include the small sample size that precludes the power of the study, suboptimal randomization method and the lack of a parallel arm of patients treated with fingolimod only within 4.5 hours of disease onset to differentiate the effect of fingolimod alone.
However, it is unethical to administer fingolimod alone to patients with acute ischemic stroke who are eligible for i.v. alteplase. The advantageous oral formulation of fingolimod for multiple sclerosis might be suboptimal for patients with stroke due to difficulty in swallowing and dysfunction of the gastrointestinal tract in some patients with stroke. The effects of fingolimod alone in preventing spontaneous hemorrhagic transformation or reducing its incidence when in combination with alteplase might be better visualized in patients with larger infarct volume. The narrow time window for managing patients with acute ischemic stroke and conducting sophisticated neuroimaging and other assessments poses a significant technical challenge. fingolimod, with or without i.v. thrombolysis, appears to provide a beneficial imp p pac ac act t t on on on c c cli li lini ni nica ca cal and radiographic outcome in these patients, and an added-on effect in patients receiving hro omb mb mbol ol olyt yt ytic ic ic the e era ra rapy p plus fingolimod.
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Nevertheless, the present data show that fingolimod was well tolerated and appeared to be safe and American Heart Association (14GRNT18970031) control patients still increased, but to the contrary, lesion volume decreased in the e e fi fi fing ng ngol ol olim im imod od od--reated patient. Fin = fingolimod.
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